MicroRNA-224 down-regulates Glycine N-methyltransferase gene expression in Hepatocellular Carcinoma.
Jung-Hsien HungChung-Hsien LiChing-Hua YehPin-Cheng HuangCheng-Chieh FangYen-Fu ChenKuo-Jui LeeChih-Hung ChouHsin-Yun ChengHsien-Da HuangMarcelo ChenTing-Fen TsaiAnya Maan-Yuh LinChia-Hung YenAnn-Ping TsouYu-Chang TyanYi-Ming Arthur ChenPublished in: Scientific reports (2018)
Glycine N-methyltransferase (GNMT) is a tumor suppressor for HCC. It is down-regulated in HCC, but the mechanism is not fully understood. MicroRNA-224 (miR-224) acts as an onco-miR in HCC. This study is the first to investigate miR-224 targeting the coding region of GNMT transcript. The GNMT-MT plasmid containing a miR-224 binding site silent mutation of the GNMT coding sequence can escape the suppression of miR-224 in HEK293T cells. Expression of both exogenous and endogenous GNMT was suppressed by miR-224, while miR-224 inhibitor enhanced GNMT expression. miR-224 counteracts the effects of GNMT on the reduction of cell proliferation and tumor growth. The levels of miR-224 and GNMT mRNA showed a significant inverse relationship in tumor specimens from HCC patients. Utilizing CCl4-treated hepatoma cells and mice as a cell damage of inflammatory or liver injury model, we observed that the decreased expression levels of GNMT were accompanied with the elevated expression levels of miR-224 in hepatoma cells and mouse liver. Finally, hepatic AAV-mediated GNMT also reduced CCl4-induced miR-224 expression and liver fibrosis. These results indicated that AAV-mediated GNMT has potential liver protection activity. miR-224 can target the GNMT mRNA coding sequence and plays an important role in GNMT suppression during liver tumorigenesis.
Keyphrases
- cell proliferation
- long non coding rna
- poor prognosis
- long noncoding rna
- gene expression
- cell cycle
- liver injury
- liver fibrosis
- binding protein
- escherichia coli
- dna methylation
- skeletal muscle
- stem cells
- induced apoptosis
- oxidative stress
- bone marrow
- ejection fraction
- signaling pathway
- newly diagnosed
- cell therapy
- endothelial cells
- risk assessment
- crispr cas
- gene therapy
- human health